future of glp-1 drugs What's next for innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 Pipeline Update: February 2025

Tadaki H, Sasase T, Fukuda S, Toriniwa Y, Harada K, Ohta T, et al

GLP-1 lawsuits primarily target pharmaceutical manufacturers that developed and marketed semaglutide and tirzepatide medications used for diabetes treatment and weight loss

[126] demonstrated in a drug clinical study in 2018 that GLP-/GIP dual agonists could significantly reduce TG and TC levels in patients compared with placebo

Many users report stronger appetite reduction within the first two weeks compared to semaglutide

They are looking for a way to escape the endless cycle of: Refills Approvals Shortages Rising copays Fear of regain if treatment stops Gastric sleeve directly addresses that